Tag: Biotechnology StocksSort
Cardium Therapeutics Generx Presentation January 2013
Cellceutix Files Amended IND for Novel p53 Anti-Cancer Drug
Jim Boeheim and Cellceutix (CTIX) Team to Fight Cancer
Clinical trials should be starting at Harvard's Dana-Farber Cancer Center in the next two months as Cellceutix looks to validate their laboratory research on Kevetrin, their novel drug in development for the treatment of drug resistant cancers. Yesterday, it was disclosed that Syracuse basketball icon Jim Boeheim has come on board the Cellceutix team in the fight against cancer.
Cellceutix (CTIX) Makes Another Breakthrough in Cancer Research
Cellceutix Corporation (OTCBB:CTIX) has regularly reported significant breakthroughs in cancer research through studies of Kevetrin, the company’s novel cancer drug in development. Amazing data has been collected by Cellceutix researchers testing Kevetrin against many cancer lines, including head & neck, prostate, lung, colon, pancreatic and leukemia.
The True Value of a SPA: An Inside Look at CorMedix
With its new Special Protocol Assessment with the U.S. Food and Drug Administration, CorMedix will be conducting Phase III research for Deferiprone as an indication for Contrast-Induced Acute Kidney Injury. Often times, the importance or value of an SPA is overlooked, but it the case of CorMedix, it certainly warrants a closer look.
A portion of the article: